Elevance Health, Inc. (NYSE: ELV) named among top 12 US stocks to buy. BofA adjusts ELV target price to $385 reflecting higher sector valuations. Q3 results show steady execution with total operating revenue reaching $50.1 billion, up 12%. Management reaffirms 2025 adjusted EPS of $30. ELV, formerly Anthem, is a leading US health company offering health insurance and whole-health solutions. Despite potential, other AI stocks may offer greater upside. For more investment options, check out the 15 Best Blue-Chip Stocks with Growing Dividends and 12 Best Dogs of the Dow to Invest in.

Read more at Yahoo Finance: BofA Adjusts Elevance Health (ELV) Target to Reflect Higher Sector Valuations